| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.05. | Xenetic Biosciences appoints James Parslow as interim CEO | 1 | Seeking Alpha | ||
| 22.05. | Xenetic Biosciences, Inc. Announces Executive Leadership Transition | 304 | ACCESSWIRE | Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company")... ► Artikel lesen | |
| 22.05. | Xenetic Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.05. | Xenetic Biosciences reports Q1 results | 1 | Seeking Alpha | ||
| 10.05. | Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update | 300 | ACCESSWIRE | Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of... ► Artikel lesen | |
| 10.05. | Xenetic Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.05. | Xenetic Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 26.04. | Xenetic Biosciences, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 22.03. | Xenetic Biosciences reports FY results | 2 | Seeking Alpha | ||
| 22.03. | Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results | 375 | ACCESSWIRE | Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with... ► Artikel lesen | |
| 22.03. | Xenetic Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Xenetic Biosciences Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
| 21.03. | Xenetic Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.02. | Xenetic Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.01. | Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform | 520 | ACCESSWIRE | - Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc.... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 6.886 |
| NVIDIA | 5.169 |
| GAMESTOP | 4.278 |
| NEL | 3.593 |
| EVOTEC | 3.168 |
| BAYER | 2.742 |
| PLUG POWER | 2.561 |
| BYD | 2.049 |
| VOLKSWAGEN | 1.437 |
| SUPER MICRO COMPUTER | 1.381 |
| BIONTECH | 1.353 |
| DEUTSCHE LUFTHANSA | 1.314 |
| RHEINMETALL | 1.276 |
| AIXTRON SE | 1.205 |
| NOVAVAX | 1.172 |
| CUREVAC | 1.097 |
| BASF | 1.014 |
| DEUTSCHE BANK | 998 |
| COMMERZBANK | 973 |
| PALANTIR TECHNOLOGIES | 940 |
| RWE | 928 |
| PAYPAL | 902 |
| TESLA | 894 |
| DEUTSCHE TELEKOM | 890 |
| THYSSENKRUPP | 888 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
